Epigenica AB Unveils EpiFinder™ GenomePro

Epigenica AB is at the forefront of epigenomic research, introducing the EpiFinder™ GenomePro, a groundbreaking product comprising advanced features designed for high throughput and multiplexing. This innovative tool aims to assist researchers in delving deep into the complex realm of histone post-translational modifications (hPTMs) and DNA methylation, achieving unprecedented results.

The EpiFinder™ GenomePro stands out by enabling the simultaneous exploration of hPTMs and DNA methylation with remarkable efficiency while ensuring accuracy in data quality. Notably, the updated version allows for the analysis of 24 samples in a single run, leveraging optimized reagents and streamlined protocols.

According to CEO Mohamad Takwa, “With EpiFinder™ GenomePro, we're setting a new standard in epigenomic research. Our vision is to deliver insights that empower researchers to address intricate biological questions at an unprecedented scale.” The platform is engineered to facilitate high-resolution data collection, which makes large-scale studies not only feasible but also cost-effective.

Key Features

The EpiFinder™ GenomePro offers a flexible design, where researchers can select hPTMs along with or without DNA methylation, adapting the framework to fit their specific research needs. The open-source data analysis pipeline further enhances accessibility, ensuring transparency and reproducibility in results.

With the capacity to provide comprehensive 192 genome-wide Chromatin Immunoprecipitation Sequencing (ChIP-Seq) profiles, this cutting-edge tool utilizes minimal sample volumes to report robust quantitative data. The reduced cost per sample affords researchers the opportunity to dive into large-scale studies more easily than ever before.

Advancing Research in Multiple Therapeutic Areas

The potential applications of the EpiFinder™ GenomePro are extensive, and it is set to fuel advancements in various therapeutic domains. By elucidating the epigenetic mechanisms that govern disease onset and progression, the product can help predict patient responses to treatments. Its ability to furnish high-resolution, broad epigenomic data facilitates the discovery of novel biomarkers and offers crucial insights into disease processes, aiding the creation of precision therapies.

Dr. Björn Reinius, an Associate Professor at the Karolinska Institute, has also praised the innovation: “The EpiFinder GenomePro kit offers an excellent method for labs with limited previous experience in ChIP-seq to obtain high-quality data without requiring significant time investment.” He elaborates that users can swiftly generate quantitative ChIP-seq libraries with minimal optimization.

Epigenica AB is dedicated to equipping researchers with essential tools for generating quantifiable data cost-effectively, thus enhancing the landscape of epigenomic research. As the life sciences technology company capitalizes on the advantages of the EpiFinder platform, it aims to contribute significantly to biomedical research, drug discovery, and the broader fields of diagnostics and therapeutics.

To learn more about how the EpiFinder™ GenomePro can transform your research methodologies, visit the official Epigenica AB website at www.epigenica.se.

About Epigenica: Founded in Stockholm, Sweden, in 2020, Epigenica is pioneering innovations in epigenetics, driven by a commitment to offer comprehensive solutions for high-throughput profiling in various research applications. At the helm is a patented technology designed for effective exploration of the epigenome, capturing valuable data that catalyze advancements across multiple domains in the life sciences.